About 200 reports

  • MONOCLONAL ANTIBODIES IN CANCER TREATMENT, OPDIVO PERFORMANCE VS. INDUSTRY, 2010-2022
  • Scope and Methodology

XOLAIR (OMALIZUMAB) Chapter ##: Pipeline Disruptors: Asthma TABLE ##-##: LEADING ASTHMA PRODUCT SALES (GLOBAL), 2016 ($ IN MILLIONS) FIGURE ##-##: ASTHMA MARKET SHOWS CORTICOSTEROIDS TREATMENT OF CHOICE, SALES BY DRUG TYPE 2010-2016 ($ MILLIONS) Chapter ##: Pipeline Dis

  • Lymphoma
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.
  • Roche Group

Gilead Sciences Disrupts HCV Market Figure ##-##: Gilead Sciences Dominates HCV Market, Displaces Current Therapies ($ millions) Bristol-Myers Squibb - Opdivo Disrupts Monoclonal Antibody Performance in Cancer Figure ##-##: Monoclonal Antibodies in Cancer Treatment, Opdivo

  • Leukemia
  • Lymphoma
  • Oncology
  • World
  • Market Size
  • 7.3. FORECAST METHODOLOGY
  • XENCOR

THE DRUG IS CURRENTLY BEING DEVELOPED IN PHASE III FOR ASTHMA AND COPD.

  • Lymphoma
  • North America
  • United States
  • MedImmune, LLC
  • Roche Group
  • DRUGS BASED ON XMAB® ANTIBODY TECHNOLOGY

THIS DRUG HAS NOW REACHED PHASE III OF CLINICAL DEVELOPMENT FOR THE TREATMENT OF ASTHMA AND COPD., ##. ##. ##. ##. ##.

  • Lymphoma
  • North America
  • United States
  • Amgen Inc.
  • MedImmune, LLC

This patent, which expires in 2032 protects to the use of masitinib in the treatment of severe persistent corticosteroid-dependent asthma and severe persistent corticosteroidresistant asthma.

  • Dermatological Condition
  • Lymphoma
  • Therapy
  • United States
  • Product Initiative

IT IS ALSO WORTH HIGHLIGHTING THAT IMMUNOTHERAPY IS BEING STUDIED NOT ONLY TO TREAT CANCER, BUT ALSO FOR SEVERAL OTHER INDICATIONS INCLUDING ASTHMA, ALLERGY AND ALZHEIMER' S DISEASE.

  • Lymphoma
  • North America
  • United States
  • Juno Therapeutics Inc.
  • Kite Pharma, Inc.
  • C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Discontinued Products
  • PIPELINE BY KYOWA HAKKO KIRIN CO LTD, H2 2017

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2017 Summary C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - C-C chemokine receptor type 4 is a protein encoded by the CCR4 gene. CCR4 is expressed on Th2 T lymphocytes and is up-regulated by T cell receptor activation. This receptor...

  • Lymphoma
  • Therapy
  • United States
  • World
  • Kyowa Hakko Kirin Co., Ltd.
  • C-C Chemokine Receptor Type 4 (C-C CKR-4 or K5-5 or CD194 or CCR4) - Discontinued Products
  • C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Dormant Products

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H1 2018 Summary C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - C-C chemokine receptor type 4 is a protein encoded by the CCR4 gene. CCR4 is expressed on Th2 T lymphocytes and is up-regulated by T cell receptor activation....

  • Lymphoma
  • Therapy
  • United States
  • World
  • Kyowa Hakko Kirin Co., Ltd.
  • Follicular Lymphoma
  • PIPELINE BY AB SCIENCE SA, H1 2018

The study lasted for ## year.

  • Lymphoma
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • DORMANT PRODUCTS, H2 2017
  • Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria.

As of May 2013, it was a preclinical stage of development for asthma and COPD.

  • Lymphoma
  • United States
  • Company
  • Company Operations
  • Product Initiative
  • Multiple Myeloma (Kahler Disease)
  • duvelisib

As of September 2014, it was in phase II stage of development for mild allergic asthma.

  • Lymphoma
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

The company' s pipeline products comprise therapies such as SP-##-##, SP-##-##, SP-##-## and SP-##-##.

  • Lymphoma
  • Oncology
  • United States
  • World
  • Acetylon Pharmaceuticals, Inc.
  • Non-Small Cell Lung Cancer
  • DEPRESSIVE DISORDER

Johnson & Johnson - Product Pipeline Review - 2016 Summary Global Markets Direct’s, ‘Johnson & Johnson - Product Pipeline Review - 2016’, provides an overview of the Johnson & Johnson’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development...

  • Infectious Disease
  • Lymphoma
  • Monoclonal Antibody
  • Therapy
  • United States

The company' s product pipeline includes PI##K GDC-##; Cantrixil (TRX-E-##-##); Trilexium (TRXE-##-##).

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Genentech, Inc.

The company' s pipeline products comprise therapies such as SP-##-##, SP-##-##, SP-##-## and SP-##-##.

  • Lymphoma
  • Oncology
  • United States
  • Product Initiative
  • Acetylon Pharmaceuticals, Inc.
  • PIPELINE BY CURIS INC, H1 2018

Inhibition of IRAK## activity has been implicated in multiple diseases including rheumatoid arthritis, systemic lupus erythematosus, gout, inflammatory bowel disease, asthma, and allergic rhinitis.

  • Lymphoma
  • Therapy
  • United States
  • World
  • Product Initiative
  • BAYER AG
  • PIPELINE BY ASTRAZENECA PLC, H1 2018

It is also developing new approaches to the treatment of asthma.

  • Cancer
  • Lymphoma
  • Therapy
  • World
  • Product Initiative
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H2 2017
  • GLOBAL MARKETS DIRECT REPORT COVERAGE

It develops inhalation products, to help patients suffering from airways diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary fibrosis and other diseases.

  • Lymphoma
  • Therapy
  • United States
  • Product Initiative
  • Pfizer Inc.

Patients will be randomized ##:##:## to one of three arms: CABOMETYX and Opdivo; CABOMETYX, Opdivo and Yervoy; or sunitinib.

  • Lymphoma
  • Renal Cancer
  • United States
  • Product Initiative
  • Bristol-Myers Squibb Company
  • PIPELINE BY ASTRAZENECA PLC, H1 2018

It is also developing new approaches to the treatment of asthma.

  • Cancer
  • Lymphoma
  • United States
  • Product Initiative
  • Idera Pharmaceuticals, Inc.

Its pharmaceutical products comprise inhaled corticosteroid for asthma, osteoporosis drugs, anti-hyperuricemia agent, and others.

  • Autoimmune Disease
  • Lymphoma
  • United States
  • World
  • Product Initiative

A Phase II randomized, double blind, placebo-controlled, crossover study to evaluate the safety and efficacy of eculizumab in subjects with mild allergic asthma was initiated in September 2007.

  • Lymphoma
  • Mental Health
  • United States
  • Product Initiative
  • Alexion Pharmaceuticals, Inc.

The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Unknown stages are ##, ##, ##, ## and ## respectively.

  • Hospital
  • Lymphoma
  • United States
  • World
  • Product Initiative

SR ONE LTD.

  • Lymphoma
  • Pharmaceutical
  • Therapy
  • United States
  • AbbVie Inc.

THIS PATENT, WHICH EXPIRES IN 2032 PROTECTS TO THE USE OF MASITINIB IN THE TREATMENT OF SEVERE PERSISTENT CORTICOSTEROID-DEPENDENT ASTHMA AND SEVERE PERSISTENT CORTICOSTEROIDRESISTANT ASTHMA.

  • Dermatological Condition
  • Lymphoma
  • Therapy
  • United States
  • Product Initiative

Its pharmaceutical products comprise inhaled corticosteroid for asthma, osteoporosis drugs, anti-hyperuricemia agent, and others.

  • Lymphoma
  • United States
  • World
  • Product Initiative
  • ChemoCentryx, Inc.

IMMUNE-RELATED AES COMPRISED GRADE ## ALT ELEVATION (N = ##), GRADE ## AST ELEVATION (N = ##), GRADE ## PNEUMONITIS (N = ##), AND GRADE ## THYROID-STIMULATING HORMONE ELEVATION (N = ##).

  • Blood Disease
  • Lymphoma
  • Vaccine
  • United States
  • Merck & Co., Inc.
  • Breast Cancer
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H2 2017 (CONTD..1), H2 2017

In Period ##, subjects were randomized in a ##:##:##:## ratio to one of four treatment groups (three dosing groups and one placebo group) for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Incyte Corporation
  • PIPELINE BY AB SCIENCE SA, H1 2018
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018

This patent, which expires in 2032 protects to the use of masitinib in the treatment of severe persistent corticosteroid-dependent asthma and severe persistent corticosteroidresistant asthma.

  • Lymphoma
  • United States
  • World
  • Company Sales
  • Product Initiative

It offers lung disease products such as Glassia used in augmentation therapy for patients with emphysema secondary to congenital alpha-## antitrypsin deficiency; Bramitob to manage chronic pulmonary infection; and Foster used for the treatment of asthma.

  • Immunology
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Baxter International Inc.